Quantifying Preferences in Drug Benefit‐Risk Decisions-Reference-Cited by-同舟云学术

Quantifying Preferences in Drug Benefit‐Risk Decisions

Published:2019-04-24 Issue:5 Volume:106 Page:955-959
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Tervonen Tommi¹,Angelis Aris²,Hockley Kimberley³,Pignatti Francesco⁴,Phillips Lawrence D.⁵

Affiliation:

1. Evidera London UK

2. Department of Health Policy and LSE HealthLondon School of Economics and Political Science London UK

3. School of Public HealthImperial College London London UK

4. European Medicines Agency Amsterdam The Netherlands

5. Department of ManagementLondon School of Economics and Political Science London UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1447

Reference67 articles.

1. European Medicines Agency (EMA).Benefit‐risk methodology (2018). Accessed December 12 2018.

2. Recommendations for benefit-risk assessment methodologies and visual representations

3. KCE.Incorporating societal preferences in reimbursement decisions: relative importance of decision criteria according to Belgian citizens (2014). Accessed December 12 2018.

4. Understanding drug preferences, different perspectives

5. Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making?

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preferences of Patients with Amyotrophic Lateral Sclerosis for Intrathecal Drug Delivery: Choosing between an Implanted Drug-Delivery Device and Therapeutic Lumbar Puncture;The Patient - Patient-Centered Outcomes Research;2023-12-14

2. Methodological guidelines and publications of benefit–risk assessment for health technology assessment: a scoping review protocol;BMJ Open;2023-12

3. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment;European Urology Open Science;2023-05

4. A Structured Benefit-Risk Assessment Operating Model for Investigational Medicinal Products in the Pharmaceutical Industry;Therapeutic Innovation & Regulatory Science;2023-04-01

5. Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force;Value in Health;2023-04